Aprotinin treatment against SARS‐CoV‐2: A randomized phase III study to evaluate the safety and efficacy of a pan‐protease inhibitor for moderate COVID‐19 - Redondo‐Calvo - 2022 - European Journal of Clinical Investigation -
Adidas Superstar Justo Munoz Hotsell, 56% OFF | www.ingeniovirtual.com